We report the results of a retrospective single-center study comparing engraftment, acute and chronic GVHD, relapse and survival in patients with malignant hematological disorders transplanted with allogeneic peripheral blood stem cells (alloPBSCT, n = 40) or bone marrow cells (alloBMT, n = 42). All transplants were T cell depleted by in vitro incubation with the Campath-1 monoclonal antibody. Primary graft failure occurred in none of the patients receiving an alloPBSCT compared with 3/42 of the recipients of an alloBMT. In addition, two patients in the alloBMT group showed no platelet engraftment. Recipients of PBSC had a more rapid recovery of neutrophils (median 14 days) compared to BM transplant recipients (median 32 days). Platelet recovery was also accelerated in PBSC recipients compared to BM recipients (11 vs 38 days). There was an increase in the incidence of grade II acute GVHD and chronic GVHD in patients after alloPBSCT (18% and 23%, respectively) compared to patients receiving alloBMT (5% and 8%, respectively). The 2-year cumulative incidence of relapse was similar in both groups (47%). At 6 months after transplantation, transplant-related mortality (TRM) was lower in PBSCT recipients than in BMT recipients. However, at a followup of 3 years TRM was similar in both groups. The disease-free survival rate at 3 years after transplantation did not differ between the groups (42% for PBSCT and 41% for BMT recipients). Our results indicate that T cell-depleted alloPBSCT compared to alloBMT is associated with a more rapid hematopoietic reconstitution and a decreased TRM at 6 months followup after transplantation. However, at a follow-up of 3 years, no sustained survival benefits were observed.
Allogeneic stem cell transplantation (alloSCT) is a curative therapy for many patients with malignant and nonmalignant hematological diseases. While bone marrow (BM) has been the dominant source of hematopoietic donor stem cells for many years, cytokine-mobilized peripheral blood cells are now increasingly used. [1] [2] [3] Results of transplantation of peripheral blood stem cells (PBSC) from HLA-identical sibling donors have demonstrated a more rapid hematopoietic recovery with less regimen-related toxicity in recipients of PBSC compared to recipients of BM. [4] [5] [6] A clear disadvantage associated with the use of non-manipulated alloPBSC grafts is the increased incidence of chronic GVHD (cGVHD) compared to alloBMT recipients. 7, 8 T cell depletion of the graft is an effective method of preventing GVHD. We have used the Campath-1 monoclonal antibody as an effective and simple method for purging donor T cells from the graft. 9 This method of T cell depletion resulted in a low incidence of acute and chronic GvHD after alloBMT. Transplantation of allogeneic peripheral blood stem cells after incubation with Campath-1 also resulted in a more rapid hematopoietic recovery compared to patients transplanted with BM stem cells. However, no long-term data with respect to GVHD and survival are yet available.
In this analysis, we report a single center comparison between T cell-depleted PBSC transplantation and T celldepleted BM transplantation with respect to engraftment, incidence and severity of GVHD, relapse and survival.
Patients and methods

Patients
Between May 1993 and December 1998, 82 consecutive patients with hematological malignancies received a first allogeneic transplantation with PBSC (n = 40) or BMT (n = 42) from an HLA-identical sibling donor at the Leiden University Medical Center. The transplant protocol was approved by the institutional Ethics Committee. Thirty-nine of the 42 BMT patients were transplanted in the period 1993-1996. The main clinical characteristics of the patients are shown in Table 1 . All patients were nursed in Hepafiltered rooms.
Donors
All patients were transplanted with stem cells from a fully HLA-matched sibling donor. PBSC donors were mobilized with Filgrastim (G-CSF) (Amgen, Thousand Oaks, CA, USA), 10 g/kg/day s.c. for 4 or 5 days. On day 4 the donor received two injections of Filgrastim. Apheresis was performed on day 5 of G-CSF administration using a continuous flow blood cell separator (Cobe Spectra; Gambro BCT; Lakewood, CO, USA). A minimum dose of 4 × 10 6
CD34
+ cells/kg of the recipient body weight was targeted for PBSC transplantation. Bone marrow was obtained from donors by standard methods and was harvested under general anesthesia. After filtering and centrifugation, the buffy coat was harvested. T cell depletion of the stem cell product (PBSC or BM) was performed by incubation with 10 mg Campath-1G for 30 minutes at room temperature under continuous agitation. The last five PBSC transplants were incubated with 10 mg Campath-1H (humanized Campath antibody).
The number of CD34 + and CD3 + cells in the graft were analyzed by flow cytometry according to the guidelines of the International Society for Hematotherapy and Graft Engineering. 10 The number of hematopoietic progenitor cells (CFU-GM) in the graft was determined as previously described.
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Transplantation
Patients were conditioned with a myeloablative regimen as described in Table 2 . Most patients received cyclophosphamide (Cy) at 60 mg/kg/day i.v., administered for 2 consecutive days (days −6 and −5) followed by single dose 
Evaluation and definition
Neutrophil engrafment was defined as the first of 2 consecutive days with an absolute neutrophil count Ͼ0.5 × 10 9 /l following a post-transplant nadir. Platelet engraftment was defined as the first of 7 consecutive days with a platelet count of Ͼ50 × 10 9 /l without transfusion. Graft failure was defined as the failure to reach an absolute number of neutrophils of 0.5 × 10 9 /l at day 60. The presence of cytomegalovirus (CMV) lower matrix protein pp65-positive leukocytes in peripheral blood was analyzed weekly for 3 months after transplantation. Positive antigenemia was defined as the presence of more than one positively stained leukocyte. Patients with a positive antigenemia test were treated with ganciclovir for 2 weeks (5 mg/kg i.v., twice a day). CMV disease was diagnosed on the basis of an inflammatory process considered to be due to CMV confirmed by immediate-early-antigen (IEA) assay or CMV cultures. 12 Assessment and grading of acute and chronic GVHD were made using the Glucksberg and Shulman criteria, respectively. 13, 14 Patients with engraftment and surviving over 90 days were evaluable for acute and chronic GVHD. Transplant-related mortality (TRM) was defined as death in continuous complete remission: event-free survival (EFS) as survival in continuous complete remission. Relapse of the disease was defined as hematological recurrence of the disease, except for CML in which a cytogenetic reappearance of the Philadelphia chromosome was also classified as a relapse. All patients received supportive care (ie antimicrobial prophylaxis, hydration, blood component support, parenteral nutrition) according to institutional protocols.
Statistical analysis
At the time of analysis the median follow-up was 39 months. The Mann-Whitney U test or the Chi-square test, when appropriate, were used to compare engraftment, transfusion requirements, hospitalization and GVHD. The timeto-event data (EFS, RR, TRM) were compared by the Kaplan-Meier method with log-rank test.
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RESULTS
Cell yield in grafts
The number of nucleated cells, CD34 + cells, CD3 + cells as well as progenitor cells (CFU-GM) were significantly higher in PBSC leukapheresis products than in BM grafts (Table 3 , P Ͻ 0.001). The number of CD3
+ cells was more than 10-fold higher in PBSC grafts than in BM grafts.
Engraftment, transfusions and hospitalization
No graft failures occurred in patients receiving PBSC grafts. In contrast, three patients in the BM group failed to achieve full engraftment. In addition, two more patients in this group failed to achieve platelet engraftment (Table 4) . Neutrophil engraftment (ANC Ͼ0.5 × 10 9 /l) was significantly faster in the PBSC group than in the BM group (median 14 vs 32 days) (P Ͻ 0.001). Similarly, platelet engraftment (platelets Ͼ50 × 10 9 /l, without transfusion) was also much faster in patients receiving PBSC than in those receiving BM (median 11 vs 38 days) (P Ͻ 0.001). Due to the faster recovery, fewer red blood cell (median 2 vs 6 units) and platelet (median 2 vs 9 units) transfusions were given in the PBSC group than in the BM group (Table  4 ; P Ͻ 0.001).
The faster hematopoietic recovery in the PBSC group resulted in a reduced duration of reverse isolation and hospitalization (median 23 days vs 37 days in the BM group, Table 4 ) (P Ͻ 0.001). 
CMV antigenemia
Sixteen donor-recipients pairs were CMV-seronegative before transplantation in both groups (Table 1) . No difference was observed in the incidence of CMV antigenemia after transplantation between the PBSC and BM group (28% vs 26%, Table 5 ). However, a trend towards a shorter time interval between the date of transplantation and CMV antigenemia was detected in the PBSC group compared to the BM group (median 42 vs 77 days, P = 0.134). No difference was observed in the incidence of relapse of antigenemia or CMV disease between both groups.
Acute and chronic GVHD
The incidence and severity of acute and chronic GVHD in both groups are shown in Table 6 . Significantly more aGVHD (уgrade II) (18% vs 5%) (P Ͻ 0.05) and chronic GVHD (23% vs 8%) (P Ͻ 0.07) was observed in the PBSC group compared to the BM group. The higher incidence of aGVHD in the PBSC group was entirely due to an excess incidence of grade II GVHD. Grades III-IV acute GVHD were only observed in one BM graft recipient and in none of the patients receiving PBSC.
Causes of death, relapse and survival
No significant difference in transplant-related mortality (TRM) was observed between the groups (PBSC 16% vs BMT 24%) (Figure 1 ). Causes of death are shown in Table  7 . In the BM group, 21 patients died, seven due to relapse and 11 due to infections. Six patients died due to a bacterial infection, four from a fungal infection and one from CMV disease. In contrast, in the PBSC group only four deaths were attributed to an infection (two due to bacterial infection, one due to viral and one due to an fungal infection) (P Ͻ 0.06). The 2-year cumulative incidence of relapse was 47% in both the PBSC and BM group (Figure 2) . However, the interval between transplantation and relapse was shorter in the PBSC group compared to the BM group. The eventfree survival (EFS) rate did not differ significantly between the two groups (Figure 3) . At 3 years after transplantation, EFS was 42% in the PBSC group and 41% in the BM group. 
Discussion
This study shows that T cell-depleted alloPBSCT with the use of the Campath-1 monoclonal antibody results in a faster engraftment than transplantation with BM donor stem cells, resulting in a shorter hospital stay, fewer blood transfusions and a reduced TRM at 6 months after transplantation. No increased incidence of severe aGVHD (grades III-IV) was observed. However, the incidence of grade II aGVHD and cGVHD was significantly increased after alloPBSCT compared to alloBMT. No differences were observed in relapse risk and disease-free survival.
Campath-1G is a rat monoclonal antibody which recognizes the CD52 antigen that is abundantly expressed on all human lymphocytes and monocytes. CD52 is a good target for cell lysis by antibody with human complement and by antibody-dependent cell-mediated cytotoxicity (ADCC). 15, 16 T cell depletion of BM with Campath-1G has been used for more than 10 years as an effective and simple method to prevent GVHD. Although between one and two log T cell depletion occurs during incubation with Campath-1G in vitro, the main T cell-depleting effect occurs in vivo by a cellular effector mechanism (ADCC). 17 Therefore it remains difficult to determine the degree of T cell depletion since measuring the number of CD3 + cells after Campath incubation only reflects the degree of complement-mediated T cell lysis in vitro. It has been demonstrated that the recovery of mononuclear cells and CD34 + cells after Campath incubation is consistently good. Graft failure is one of the major disadvantages associated with the use of Campath as a method for T cell depletion in alloBMT. 15, 16 In our BM group, 12% of the patients (5/42) did not achieve full engraftment (ANC Ͼ0.5 × 10 9 /l or platelets Ͻ50 × 10 9 /l). In contrast, all patients receiving PBSCT had consistent and rapid hematopoietic reconstitution. This is in agreement with our preliminary experience with patients receiving alloPBSCT. 18 Apparently the engraftment delaying effect associated with Campath-incubated BM can be overcome by increasing the number of hematopoietic progenitor and/or CD3 + cells in the graft. A common observation in our alloPBSCT patients is the earlier engraftment of platelets than of neutrophils (median 11 vs 14 days). Similar engraftment kinetics of platelets and neutrophils have been observed in other studies. 5, 19, 20 However, data from a large retrospective analysis of 288 alloPBSCT patients did not confirm this phenomenon. 21 The faster hematopoietic recovery after alloPBSCT compared to alloBMT in our study was reflected by reduced transfusion requirements and hospital stay in this treatment group. Patients were discharged 14 days earlier after alloPBSCT than after BMT.
The incidence of aGVHD (grades II-IV) and cGVHD in alloBMT after incubation with Campath-1G to deplete the T cells from the graft was 5% and 8%, respectively. An important finding in our study was the increase in grade II acute GVHD, and chronic GVHD in patients receiving PBSCT (18% and 23%, respectively), compared to the BMT group. This increase was mainly confined to GVHD of the skin and only one patient had cGVHD of the liver. The incidence of GVHD in our PBSCT patients was, however, still much lower than in patients after non-manipulated alloPBSCT, for whom the incidence of severe acute and chronic GVHD was 35% and 70%, respectively. 21 The increase of GVHD after T cell-depleted alloPBSCT may be due to the five-to 10-fold higher numbers of CD34 + and CD3 + cells in the PBSC grafts compared to the BM grafts. Six recipients of BM received i.v. Campath pretransplant compared to one PBSC patient. Further analysis of the incidence of GVHD in these patients revealed no difference in GVHD compared to the other 36 BMT patients. This is probably due to the concomitant Campath incubation of the transplant in both groups.
Patients receiving BM or PBSC grafts had a similar incidence of CMV antigenemia. However, there was a trend towards an earlier onset of CMV antigenemia after transplantation in the PBSCT group compared to the BMT group. This may be a direct consequence of the more rapid recovery of leukocytes, since the diagnostic test for CMV was performed on leukocytes. Alternatively, rapid hematopoietic recovery after PBSCT may result in reactivation of Bone Marrow Transplantation latent CMV, a phenomenon which has been described in vitro. 22 Importantly, no difference was observed in the incidence of CMV disease in the BM and PBSC groups.
The rapid hematopoietic recovery after alloPBSCT resulted in a lower TRM at 6 months after transplantation, due to a decrease in early infections. However, at 3 years after transplantation no difference in TRM was observed between the BM and PBSC group (Figure 1) . This was probably due to the increased incidence of GVHD after alloPBSCT resulting in the increased use of immunosuppressive drugs which contributed to a higher percentage of death.
Several reports have suggested an increased graft-versusleukemia effect after allo PBSCT. [23] [24] [25] In our study, no differences were seen in relapse risks between groups, despite the higher incidence of GVHD in the PBSC group ( Figure  2) . Relapse was observed earlier after alloPBSCT. This may be due to the more intensive diagnostic follow-up protocols we have used since 1997, ie patients after alloSCT are now monitored every 3 months for relapse at molecular, cytogenetic and cellular levels. With this protocol, relapses of disease (in particular CML) are detected earlier compared to patients transplanted before 1997. Importantly, the earlier onset of relapse in the PBSC group may also contribute to the lower TRM observed at 6 months. Data of TRM and relapse risks are reflected in the event-free survival curves, that show no difference between final outcome in patients after alloPBSCT compared to BM controls ( Figure 3 ).
In conclusion, T cell-depleted alloPBSCT with the use of the Campath monoclonal antibody results in a faster hematopoietic recovery than after alloBMT. However, the more rapid engraftment was not associated with a better disease-free survival after longer follow-up.
